Last Updated on October 6, 2024 by The Health Master
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out at the company’s solid oral formulation facility (F-4) at Jarod, Vadodara during the period from December 8 -16, 2022.
This was pre-approval inspection to cover Alembic’s solid oral drug products for which ANDAs were filed with USFDA.
The company had also started receiving approvals manufactured at this facility. Alembic has a total of five drug product manufacturing facilities and two drug substance manufacturing facilities. All these facilities are inspected and accepted by USFDA.
USFDA issues EIR to Indoco Remedies, Goa
USFDA gives approval for Pupil-dilating spray
USFDA gives approval for this first RSV Vaccine
USFDA gives tentative nod for ARV oral, Dolutegravir
USFDA declines to approve this Hormone Disorder therapy
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
Requirement of IP, IPRS & Impurity Standards to be part of joint inspection
CDSCO approves Discovery Solutions HSV type 1 & 2 detection kit
Marketing approval for Oncology medicines from Philippines, Iraq
USFDA gives approval for Pupil-dilating spray
NPPA to fix ceiling prices based on existing methodology
Drug recall: 24,194 Prefilled Syringes of generic medication recalled due to this reason
NABL accredits more Laboratories with a total number of 8,386 Laboratories
National Medical Devices Policy 2023: Salient Features
All Blood Centres / Banks to have NAT-PCR test by 2025
Moving towards zero counterfeiting to ease traceability and authentication
